A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer

CONCLUSION: The combination of capivasertib and abiraterone acetate had an acceptable tolerability profile consistent with the known profile of each agent. These data support further evaluation of capivasertib and abiraterone acetate in patients with advanced prostate cancer.PMID:36572571 | DOI:10.1016/j.clgc.2022.11.017

Source: Clinical Prostate Cancer - December 26, 2022 Category: Cancer & Oncology Authors: Neal Shore Bego ña Mellado Satish Shah Ralph Hauke Dan Costin Nabil Adra Marie Cullberg Carlos Fernandez Teruel Thomas Morris Source Type: research